Modality
Degrader
MOA
KIF18Ai
Target
GPRC5D
Pathway
Neuroinflam
Hemophilia AHCCMDD
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
May 2019
→ May 2031
Phase 1Current
NCT04084793
782 pts·MDD
2025-08→2031-05·Recruiting
NCT06974514
2,046 pts·Hemophilia A
2019-05→TBD·Completed
2,828 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-105.1y awayPh2 Data· MDD
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1/2
Complet…
P1/2
Recruit…
Catalysts
Ph2 Data
2031-05-10 · 5.1y away
MDD
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04084793 | Phase 1/2 | MDD | Recruiting | 782 | SeizFreq |
| NCT06974514 | Phase 1/2 | Hemophilia A | Completed | 2046 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D |